BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33805713)

  • 1. Doxorubicin-Loaded Gold Nanoarchitectures as a Therapeutic Strategy against Diffuse Intrinsic Pontine Glioma.
    Ung C; Tsoli M; Liu J; Cassano D; Pocoví-Martínez S; Upton DH; Ehteda A; Mansfeld FM; Failes TW; Farfalla A; Katsinas C; Kavallaris M; Arndt GM; Vittorio O; Cirillo G; Voliani V; Ziegler DS
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33805713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
    Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
    J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of protein synthesis inhibitor omacetaxine in pediatric brainstem gliomas.
    Chen Y; Khan A; Katsinas C; Michniewicz F; Goldberg J; Franshaw L; Tsoli M; Ziegler DS
    Neurooncol Adv; 2024; 6(1):vdae029. PubMed ID: 38550394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brainstem blood brain barrier disruption using focused ultrasound: A demonstration of feasibility and enhanced doxorubicin delivery.
    Alli S; Figueiredo CA; Golbourn B; Sabha N; Wu MY; Bondoc A; Luck A; Coluccia D; Maslink C; Smith C; Wurdak H; Hynynen K; O'Reilly M; Rutka JT
    J Control Release; 2018 Jul; 281():29-41. PubMed ID: 29753957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal delivery of nanoliposomal SN-38 for treatment of diffuse midline glioma.
    Sasaki T; Watanabe J; He X; Katagi H; Suri A; Ishi Y; Abe K; Natsumeda M; Frey WH; Zhang P; Hashizume R
    J Neurosurg; 2023 Jun; 138(6):1570-1579. PubMed ID: 36599085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI-guided focused ultrasound enhances drug delivery in experimental diffuse intrinsic pontine glioma.
    Ishida J; Alli S; Bondoc A; Golbourn B; Sabha N; Mikloska K; Krumholtz S; Srikanthan D; Fujita N; Luck A; Maslink C; Smith C; Hynynen K; Rutka J
    J Control Release; 2021 Feb; 330():1034-1045. PubMed ID: 33188825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance.
    Deligne C; Hachani J; Duban-Deweer S; Meignan S; Leblond P; Carcaboso AM; Sano Y; Shimizu F; Kanda T; Gosselet F; Dehouck MP; Mysiorek C
    Fluids Barriers CNS; 2020 Jun; 17(1):37. PubMed ID: 32487241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma.
    Tsoli M; Liu J; Franshaw L; Shen H; Cheng C; Jung M; Joshi S; Ehteda A; Khan A; Montero-Carcabosso A; Dilda PJ; Hogg P; Ziegler DS
    Oncotarget; 2018 Jan; 9(7):7541-7556. PubMed ID: 29484131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
    Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
    Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas.
    Ehteda A; Khan A; Rajakumar G; Vanniasinghe AS; Gopalakrishnan A; Liu J; Tsoli M; Ziegler DS
    Mol Cancer Ther; 2023 Dec; 22(12):1413-1421. PubMed ID: 37683275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functionalized Macrophage Exosomes with Panobinostat and PPM1D-siRNA for Diffuse Intrinsic Pontine Gliomas Therapy.
    Shan S; Chen J; Sun Y; Wang Y; Xia B; Tan H; Pan C; Gu G; Zhong J; Qing G; Zhang Y; Wang J; Wang Y; Wang Y; Zuo P; Xu C; Li F; Guo W; Xu L; Chen M; Fan Y; Zhang L; Liang XJ
    Adv Sci (Weinh); 2022 Jul; 9(21):e2200353. PubMed ID: 35585670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma.
    Zhao G; Newbury P; Ishi Y; Chekalin E; Zeng B; Glicksberg BS; Wen A; Paithankar S; Sasaki T; Suri A; Nazarian J; Pacold ME; Brat DJ; Nicolaides T; Chen B; Hashizume R
    Acta Neuropathol Commun; 2022 Oct; 10(1):150. PubMed ID: 36274161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polo-like Kinase 1 as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma.
    Amani V; Prince EW; Alimova I; Balakrishnan I; Birks D; Donson AM; Harris P; Levy JM; Handler M; Foreman NK; Venkataraman S; Vibhakar R
    BMC Cancer; 2016 Aug; 16():647. PubMed ID: 27538997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas.
    Zuo P; Li Y; He C; Wang T; Zheng X; Liu H; Wu Z; Zhang J; Liao X; Zhang L
    Front Immunol; 2023; 14():1145706. PubMed ID: 37251413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances and Clinical Trials Update in the Treatment of Diffuse Intrinsic Pontine Gliomas.
    Dalle Ore C; Coleman C; Gupta N; Mueller S
    Pediatr Neurosurg; 2023; 58(5):259-266. PubMed ID: 36642062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
    Akamandisa MP; Nie K; Nahta R; Hambardzumyan D; Castellino RC
    Neuro Oncol; 2019 Jun; 21(6):786-799. PubMed ID: 30852603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combined approach of convection-enhanced delivery of peptide nanofiber reservoir to prolong local DM1 retention for diffuse intrinsic pontine glioma treatment.
    Bellat V; Alcaina Y; Tung CH; Ting R; Michel AO; Souweidane M; Law B
    Neuro Oncol; 2020 Oct; 22(10):1495-1504. PubMed ID: 32301996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
    Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
    EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry.
    Gits HC; Anderson M; Stallard S; Pratt D; Zon B; Howell C; Kumar-Sinha C; Vats P; Kasaian K; Polan D; Matuszak M; Spratt DE; Leonard M; Qin T; Zhao L; Leach J; Chaney B; Escorza NY; Hendershot J; Jones B; Fuller C; Leary S; Bartels U; Bouffet E; Yock TI; Robertson P; Mody R; Venneti S; Chinnaiyan AM; Fouladi M; Gottardo NG; Koschmann C
    Acta Neuropathol Commun; 2018 Jul; 6(1):67. PubMed ID: 30049282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent.
    Halvorson KG; Barton KL; Schroeder K; Misuraca KL; Hoeman C; Chung A; Crabtree DM; Cordero FJ; Singh R; Spasojevic I; Berlow N; Pal R; Becher OJ
    PLoS One; 2015; 10(3):e0118926. PubMed ID: 25748921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.